Published in Dermatol Surg on June 24, 2013
Prevalence and Mortality of Melanoma in Oklahoma Among Racial Groups, 2000-2008. J Okla State Med Assoc (2016) 0.79
Commentary: malignant melanoma in pigmented skin: does the current interventional model fit a different clinical, histological, and molecular entity? Dermatol Surg (2013) 0.75
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol (2008) 2.38
Endometrial regenerative cells: a novel stem cell population. J Transl Med (2007) 2.19
Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis (2005) 1.93
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. Br J Haematol (2011) 1.69
Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med (2009) 1.62
Novel small interfering RNA-containing solution protecting donor organs in heart transplantation. Circulation (2009) 1.60
Cutaneous sarcoidosis and malignancy: An association between sarcoidosis with skin manifestations and systemic neoplasia. Dermatol Online J (2011) 1.49
Polycystic ovary syndrome: focus on platelets and prothrombotic risk. South Med J (2011) 1.44
Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. Expert Opin Biol Ther (2013) 1.44
Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol (2003) 1.41
Inflammatory and immune-related conditions associated with Waldenström macroglobulinemia: a single center experience. Leuk Lymphoma (2014) 1.39
Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia? J Transl Med (2008) 1.27
Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cell Immunol (2010) 1.19
Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol (2003) 1.11
Feasibility investigation of allogeneic endometrial regenerative cells. J Transl Med (2009) 1.10
Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions. J Transl Med (2010) 1.09
Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem (2006) 1.07
Peripheral blood immunophenotypic analysis as a diagnostic tool for large granular lymphocyte leukemia. Leuk Lymphoma (2012) 1.07
Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther (2006) 1.06
A case of polycythemia rubra vera transforming into chronic phase JAK2 V617F mutation-negative Philadelphia chromosome-positive chronic myelogenous leukemia. Leuk Lymphoma (2013) 1.06
Risk factors for gallbladder cancer and cholangiocarcinoma: similarities, differences and updates. J Gastrointest Cancer (2012) 1.05
A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood (2009) 1.04
Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Biophys Res Commun (2008) 1.03
Association between Helicobacter pylori infection and pancreatic cancer. A cumulative meta-analysis. JOP (2011) 1.03
Incidence of second primary malignancies in patients with esophageal cancer: a comprehensive review. Curr Med Res Opin (2013) 1.03
Tumor vaccines in 2010: need for integration. Cell Immunol (2010) 1.02
Cord blood in regenerative medicine: do we need immune suppression? J Transl Med (2007) 0.97
Endometrial regenerative cells for treatment of heart failure: a new stem cell enters the clinic. J Transl Med (2013) 0.96
Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol (2010) 0.96
Lasers, stem cells, and COPD. J Transl Med (2010) 0.95
Generation of therapeutic dendritic cells and regulatory T cells for preventing allogeneic cardiac graft rejection. Clin Immunol (2008) 0.95
A novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitis. PLoS One (2012) 0.94
Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. J Immunol (2003) 0.93
Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol (2007) 0.93
Comparison of endometrial regenerative cells and bone marrow stromal cells. J Transl Med (2012) 0.92
Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med (2008) 0.92
Does bortezomib induce de facto varicella zoster virus reactivation in patients with multiple myeloma? J Clin Oncol (2009) 0.91
LF15-0195 generates tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK activity. J Leukoc Biol (2003) 0.91
Immune alterations in malignant melanoma and current immunotherapy concepts. Expert Opin Biol Ther (2013) 0.91
Small interfering RNA targeting RelB protects against renal ischemia-reperfusion injury. Transplantation (2009) 0.89
Details of left ventricular remodeling and the mechanism of paradoxical ventricular septal motion after coronary artery bypass graft surgery. J Invasive Cardiol (2011) 0.89
Adenosquamous carcinoma of the pancreas: a distinct clinicopathologic entity. South Med J (2010) 0.89
Human umbilical cord blood-derived mononuclear cell transplantation: case series of 30 subjects with hereditary ataxia. J Transl Med (2011) 0.88
RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Ther (2010) 0.88
Successful penile replantation with adjuvant hyperbaric oxygen treatment. Urology (2007) 0.87
Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J (2008) 0.87
Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer (2012) 0.87
Malignant melanoma in African-Americans. Dermatol Online J (2009) 0.86
Incidence of second primary malignancies in patients with treated head and neck cancer: a comprehensive review of literature. Curr Med Res Opin (2012) 0.86
Inhibition of intracranial glioma growth by endometrial regenerative cells. Cell Cycle (2009) 0.85
Small cell lung cancer with paraneoplastic lipase production. South Med J (2010) 0.85
Autoimmune manifestations in large granular lymphocyte leukemia. Clin Lymphoma Myeloma Leuk (2012) 0.85
A simple and reliable method to blood type monkeys using serum samples. Transpl Int (2009) 0.85
Th1/Th2 xenogenic antibody responses are associated with recipient dendritic cells. Microsurgery (2007) 0.84
An unusual presentation of a carcinoid tumor of the common bile duct. JOP (2013) 0.84
Circulating endothelial progenitor cells: a new approach to anti-aging medicine? J Transl Med (2009) 0.84
A novel allergen-specific therapy for allergy using CD40-silenced dendritic cells. J Allergy Clin Immunol (2010) 0.84
Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer. JOP (2014) 0.84
Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma. Expert Opin Pharmacother (2011) 0.83
Chasing the reflected wave back into the heart: a new hypothesis while the jury is still out. Vasc Health Risk Manag (2011) 0.83
Normal values of regional and global myocardial wall motion in young and elderly individuals using navigator gated tissue phase mapping. Age (Dordr) (2013) 0.83
Hepatoid variant of pancreatic cancer: insights from a case and literature review. JOP (2013) 0.83
Resistance of neonatal porcine Sertoli cells to human xenoantibody and complement-mediated lysis is associated with low expression of alpha-Gal and high production of clusterin and CD59. Xenotransplantation (2010) 0.82
Novel vaccination for allergy through gene silencing of CD40 using small interfering RNA. J Immunol (2008) 0.82
Acute gout during treatment with paclitaxel for metastatic melanoma. Rheumatology (Oxford) (2009) 0.82
Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide. Leuk Res (2011) 0.81
Fluorodeoxyglucose-induced allergic reaction: a case report. J Oncol Pharm Pract (2012) 0.81
Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? J Transl Med (2011) 0.81
Resistance to anti-xenogeneic response by combining alpha-Gal silencing with HO-1 upregulation. Transpl Immunol (2008) 0.80
Cotransplantation with xenogenetic neonatal porcine sertoli cells significantly prolongs islet allograft survival in nonimmunosuppressive rats. Transplantation (2009) 0.80
Induction of RNA interference in dendritic cells. Immunol Res (2004) 0.80
On the missing link between inflammation and cancer. Dermatol Online J (2011) 0.80
The cutaneous epidermal growth factor network: Can it be translated clinically to stimulate hair growth? Dermatol Online J (2009) 0.80
Vitamin B12 deficiency in patients undergoing bariatric surgery: preventive strategies and key recommendations. Surg Obes Relat Dis (2013) 0.80
Kidney cancer therapy: new perspectives and avenues. Expert Opin Pharmacother (2006) 0.79
Exogenous endothelial cells as accelerators of hematopoietic reconstitution. J Transl Med (2012) 0.79
High-grade solitary extramedullary plasmacytoma arising in skeletal muscle of a kidney transplant recipient. Leuk Res (2011) 0.79
Cholangiocarcinoma and paraneoplastic hypercalcemia: a lethal combination revisited. South Med J (2010) 0.79
Synchronous tumors: adenosquamous carcinoma of pancreas and GIST of stomach. J Gastrointest Cancer (2011) 0.79
Western variant of brain intravascular lymphoma displaying three distinct evolutive radiologic stages. Conn Med (2014) 0.79
Chronic lymphocytic leukemia presenting with cholecystitis-like symptoms and gallbladder wall invasion. South Med J (2010) 0.79
Immune effects of mesenchymal stem cells: implications for Charcot-Marie-Tooth disease. Cell Immunol (2008) 0.79
Adult biphasic pulmonary blastoma. Conn Med (2013) 0.79
Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide. Leuk Res (2010) 0.78
Acute Wernicke encephalopathy and sensorineural hearing loss complicating bariatric surgery. Conn Med (2012) 0.78
Immune alterations and immunotherapy prospects in head and neck cancer. Expert Opin Biol Ther (2013) 0.78
Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid (2008) 0.78
Immune alterations in untreated and treated myelodysplastic syndrome. Expert Opin Drug Saf (2011) 0.77
Hepatitis associated aplastic anemia: case report and discussion. Conn Med (2014) 0.77
Neuroblastoma with a solitary intraventricular brain metastasis visualized on I-123 MIBG scan. J Neuroimaging (2012) 0.77
Anti-CD(45)RB monoclonal antibody induces immunologic toleration by suppressing dendritic cells. Transpl Immunol (2009) 0.77
What are the latest pharmacotherapy options for small bowel adenocarcinoma? Expert Opin Pharmacother (2014) 0.77
Synergistic tolerance induced by LF15-0195 and anti-CD45RB monoclonal antibody through suppressive dendritic cells. Transplantation (2003) 0.77
Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma. Expert Opin Pharmacother (2013) 0.77